Insmed to Present at the Cowen and Company 38th Annual Health Care Conference
07 Mars 2018 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that a member of the management team will
present at the Cowen and Company 38th Annual Health Care Conference
in Boston, MA on Wednesday, March 14,
2018 at 10:40 a.m. ET.
The presentation will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcast will be archived for a period of 90
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company
focused on the unmet needs of patients with rare diseases. The
Company’s lead product candidate is ALIS, which is in late-state
development for adult patients with treatment refractory NTM lung
disease caused by MAC, which is a rare and often chronic infection
that is capable of causing irreversible lung damage and can be
fatal. Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase
1 with therapeutic potential in non-cystic fibrosis bronchiectasis
and other inflammatory diseases, and INS1009, an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:Blaine Davis Insmed Incorporated (908) 947-2841
blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Août 2023 à Août 2024